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1 
Abstract 
 
Efforts to establish a reliable and valid case definition for myalgic encephalomyelitis and chronic 
fatigue syndrome (ME and CFS) have been complicated by an over-reliance on clinical 
consensus, and inconsistent application of established case definitions by researchers across 
study sites. This has resulted in the absence of an empirically-based case definition for ME and 
CFS, as well as failed replication studies on potential diagnostic tests and biomarkers. One step 
toward an empirically-driven case definition is determining which symptoms best discriminate 
between patients with ME and CFS versus controls. Post-exertional malaise (PEM) is considered 
a cardinal symptom of ME and CFS and is either required or included in many previously 
proposed case definitions. PEM refers to the symptom exacerbation and impairment/sickness that 
follows physical exertion or cognitive effort. PEM is typically assessed subjectively, with a 
patient describing his or her experience to a physician or on a self-report measure. To date, there 
have been no meta-analyses of the findings from studies that investigate PEM differences 
between patients and controls. A meta-analysis of odds ratios (association between patient status 
and PEM status) and a number of potential moderators (i.e., study level characteristics) of effect 
size were conducted for a total of 31 studies. PEM was found to be 10.4 times more likely to be 
associated with an ME and CFS diagnosis than with control status. Significant moderators of 
effect size included patient recruitment strategy and control selection. These findings strongly 
suggest that PEM should be considered a cardinal symptom of ME and CFS, and the 
implications of the moderator analyses are discussed.  
 
 
 
 
 
2 
Introduction 
 
Overview of Myalgic Encephalomyelitis and Chronic Fatigue Syndrome 
 
Myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS) are debilitating 
illnesses (Nacul, Lacerda, Campion et al., 2011) characterized by profound fatigue, 
neurocognitive dysfunction, unrefreshing sleep, and a worsening of the symptom complex 
following mental or physical activity; secondary symptoms include pain and immune, 
autonomic, and neuroendocrine dysfunction (Carruthers et al., 2003).  The illness has been 
referred to as chronic fatigue syndrome (CFS) (Fukuda et al., 1994), myalgic encephalomyelitis 
or encephalopathy (ME) (Ramsay, 1988), ME/CFS (Carruthers et al., 2003), and most recently as 
systemic exertion intolerance disease (SEID) (Institute of Medicine, 2015). For the purposes of 
the present paper, the term “ME and CFS” will be utilized.  
About one million adults in the United States are believed to have ME and CFS, and the 
illness has been found to disproportionally affect women (Reyes et al., 2003) and ethnic 
minorities (Steele et al., 1998; Jason, Richman et al., 1999). ME and CFS also affect children and 
adolescents (Crawley, Emond & Sterne, 2011), although research on pediatric populations is 
limited. Onset of the illness can be sudden or gradual (De Becker, McGregor & Meirleir, 2002), 
and the etiology of the illness remains controversial (Afari & Buchwald, 2003; Erlwein et al., 
2010). Because the cause of the condition remains unknown, individuals with ME and CFS are 
often met with disbelief and are stigmatized by medical professionals, employers, friends, and 
family (Dickson, Knussen, & Flowers, 2007). Early psychogenic explanations for the illness 
suggested that patients were malingerers, and that the symptoms experienced were a result of the 
desire to remain sick (Abbey, 1993) and/or were the result of deconditioning due to a learned 
fear of activity (Clark & White, 2005). In contrast, following the first well-publicized outbreak in 
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the US, other researchers suggested the condition was most likely linked to a virus (Buchwald et 
al., 1992).  
A number of potential risk factors for ME and CFS onset have been identified. The 
variables with the most empirical support are female gender (Clark, Goodwin, Stansfeld, Hotopf 
& White, 2011; Harvey, Wadsworth, Wessely & Hotopf, 2008; Pheby & Saffron, 2009; Viner & 
Hotopf, 2004) and ethnic minority status (Jason, Richman et al., 1999). The findings regarding 
socioeconomic status are mixed (Huibers et al., 2004; Viner & Hotopf), with prevalence studies 
based on samples referred by physicians suggesting that ME and CFS are more likely to affect 
middle and upper class individuals (Lloyd, Hickie, Boughton, Spencer & Wakefield, 1990; 
Reyes et al., 1997), and studies based on community-based samples finding that lower 
educational and occupational status are associated with greater intensity of fatigue and other ME 
and CFS symptoms (Jason, Richman et al., 1999; Reyes et al., 2003).  
Although atypical immune manifestations (Fletcher et al., 2010; Klimas & Koneru, 2007; 
Maher, Klimas, & Fletcher, 2005) and neurocognitive (Hou et al., 2014; Michiels & Cluydts, 
2001), central nervous system (Gur & Oktayoglu, 2008; Nakatomi et al., 2014; Natelson, Cohen, 
Brassloff, & Lee, 1993) and autonomic dysfunction (Hurwitz et al., 2010; Newton et al., 2007) 
have been documented in ME and CFS samples, there is no universally accepted biomarker or 
objective diagnostic test for the illness. Failed replications are common within the field due to 
the heterogeneous, non-comparable patient samples used across studies, a potential consequence 
of varying inclusion criteria and continued controversy over the actual case definition for the 
illness (Jason et al., 2012). Multiple research and clinical case definitions have been proposed, 
with a recent count by Brurberg, Fonhous, Larun, Flottorp and Malterud (2014) placing the 
number at 20 definitions, with no consensus to date on a singular definition. Further issues arise 
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when research groups that intend to utilize the same case definition vary drastically in their 
operationalization of the definitions (Christley, Duffy & Martin, 2012). The issue of 
heterogeneous patient samples has plagued the research community since the Centers for Disease 
Control and Prevention’s (CDC) publication of the first diagnostic criteria for CFS (Holmes et 
al., 1988).  
Thus, there continues to be a lack of clarity about ME and CFS on the part of researchers, 
and the subsequent lack of clinical knowledge imparted to medical providers. The illness is 
underrepresented in American medical schools (Jason, Paavola, Porter & Morello, 2010), with 
ME and CFS-related content largely absent from curricula, and the majority of American 
medical programs lacking faculty with research or clinical expertise in ME and CFS (Peterson et 
al., 2013). Not surprisingly, physicians surveyed about the illness tend to rate themselves as 
lacking basic knowledge, and as feeling unprepared to treat patients presenting with ME and 
CFS symptoms (Bowen, Pheby, Charlett & McNulty, 2005; Brimmer, Fridinger, Lin & Reeves, 
2010). Although a number of potential treatments have been investigated, the issues with 
criterion variance as outlined above have led to treatment studies with a number of limitations 
(Kindlon, 2011). 
ME and CFS Case Definitions 
 
The heterogeneous patient samples used in ME and CFS research may be a product of the 
vague and poorly operationalized diagnostic criteria that have been established (Jason, King et 
al., 1999). Since the illness became formally recognized as CFS in the late 1980s in the US 
following reports of cluster outbreaks in Nevada (Buchwald et al., 1992) and New York (Bell, 
Bell, & Cheney, 1994), consensus for a singular case definition has yet to be reached by 
researchers, practitioners and patient advocates. Thus, the diagnosis of ME and CFS is an 
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exclusionary process that relies heavily on self-reported symptom profiles (Afari & Buchwald, 
2003). Therefore, selecting the cardinal or core symptoms of the illness and developing a 
standardized process for assessing these symptoms is vital (King & Jason, 2004). Many attempts 
have been made to clarify and define a case of ME and CFS since the late 1980s.  
 The Holmes et al. CFS criteria (1988) require a patient to experience persistent, 
unexplained fatigue at least 50% of the time with a definite onset, accompanied by eight out of 
11 definitional symptoms. These criteria have been criticized as vague and poorly 
operationalized, which has led to inconsistent application by clinicians and researchers (Fukuda 
et al., 1994). Further, by placing the definitional symptom threshold so high, the Holmes criteria 
may inadvertently select for individuals with primary psychiatric explanations for their fatigue 
(Katon & Russo, 1992).  
 In the early 1990s, a group of British researchers published what is referred to as the 
Oxford criteria (Sharpe et al., 1991). The primary focus of this definition is the symptom of 
fatigue, with little specificity about other minor symptoms. Severe and disabling fatigue that has 
been present for at least six months, 50% of the time, is the sole criterion, although the authors 
suggest that common co-occurring symptoms include muscle pain, mood disturbance and sleep 
disturbance. Although these criteria are quite broad, the Oxford definition has been one of the 
applied case definitions in the study of ME and CFS (Dinos et al., 2009). However, an NIH-
appointed panel recently recommended the Oxford definition be retired due to its lack of 
specificity (Green, Cowan, Elk, O’Neil, & Rasmussen, 2015).   
In response to the criticisms of the Holmes et al. (1988) case definition, the CDC 
convened an international working group to improve upon these diagnostic criteria, which 
resulted in the development of the Fukuda et al. (1994) criteria. The improved criteria have also 
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been criticized as vague and clinically unhelpful (De Becker, McGregor, & De Meirleir, 2002; 
Jason, King et al., 1999), lacking specific guidelines or operationalization. Further, the Fukuda et 
al. criteria are polythetic, meaning that individuals who meet the criteria will not necessarily 
have common features. To meet criteria, an individual must have at least six months of 
unexplained persistent fatigue of new or definite onset, experienced concurrently with just four 
out of eight definitional symptoms (i.e. unrefreshing sleep, multijoint pain, muscle pain, 
headaches, post-exertional malaise, lymph node pain, impairment in memory and concentration, 
sore throat). Further, this symptom complex must cause “substantial reductions in functioning.” 
The Fukuda criteria, with minor updates made by Reeves et al. (2003), remain the most 
universally utilized criteria to date for research and clinical purposes.  
In an attempt to operationalize the fatigue, symptom complex, and substantial reductions 
required by Fukuda et al. (1994)/Reeves et al. (2003), the CDC developed the Empiric criteria 
(Reeves et al., 2005), which specifies the use of validated self-report measures and cut-off scores 
to aid in diagnosis. The first community-based epidemiological study that utilized these criteria 
raised the CDC’s estimated prevalence rate of CFS from 0.24% (Reyes et al., 2003) to 2.54% of 
the population (Reeves et al., 2007), which was also significantly higher than previous outside 
estimates of 0.42% (Jason, Richman et al., 1999). This led many to question the validity of the 
criteria, and Jason, Najar, Porter, and Reh (2009) found that the Empiric criteria incorrectly 
identified 38% of a sample with primary major depressive disorder as having CFS due to the lack 
of specificity of this case definition.   
In 2003, an international group working independently of the CDC developed new 
criteria in which the condition was explicitly labeled ME/CFS (Carruthers et al., 2003). In 
contrast to the polythetic CDC CFS case definitions, this new ME/CFS criteria, referred to as the 
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Clinical Canadian Criteria (CCC), require two of the symptoms thought to be core to the illness 
to be present for a diagnosis: post-exertional malaise and neurocognitive impairment. To meet 
the CCC, a person must experience post-exertional malaise, at least two neurocognitive 
symptoms, at least one symptom indicating sleep dysfunction, at least one symptom indicating 
significant bodily pain, and at least one symptom from two of the following three categories: 
autonomic, neuroendocrine and immune manifestations. Additionally, this symptom complex 
must result in “substantial reduction” of an individual’s functioning. As these criteria require 
specific symptoms, they may select for a more homogenous group of individuals than the 
polythetic approach of the Holmes et al. (1988) and Fukuda et al. (1994) case definitions. Jason, 
Brown et al. (2012) compared those meeting the CCC case definition to those not meeting the 
CCC but meeting the Fukuda et al. (1994) criteria only. Findings indicated that the ME/CFS case 
definition identified individuals with more severe symptoms and greater functional disability 
than those meeting only the Fukuda criteria. However, the CCC still lack operationalization with 
no guidelines regarding frequency or severity thresholds for required symptoms (Jason, Evans, 
Porter et al., 2010). Therefore, although the CCC may identify a more homogenous sample with 
regards to what symptoms are occurring, the intensity of these symptoms could range 
significantly.  
A more recently proposed set of criteria (Carruthers et al., 2011) were described by the 
authors as an update to the ME/CFS Clinical Canadian Criteria (CCC) (Carruthers et al., 2003). 
The ME International Consensus criteria (ME-ICC) require an individual to experience post-
exertional malaise, at least one symptom out of three of four distinct neurological domains, at 
least one symptom out of three of five distinct immune domains, and at least one energy 
production symptom. Additionally, an individual’s functioning must be reduced by 50% 
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compared to their pre-illness activity level. Brown, Jason, Evans and Flores (2013) found that 
these criteria identified a more impaired and homogenous group than the Fukuda criteria (1994), 
although rates of psychiatric comorbidity were also higher in the ME-ICC group. This aligned 
with Katon and Russo’s (1992) conclusion that with increased symptom requirements, 
psychiatric comorbidity becomes more likely.  
Finally, in early 2015, the Institute of Medicine released a report recommending a new 
case definition, and also a new illness label: systemic exertion intolerance disease (SEID). This 
label is notable for its use of the term ‘disease,’ its removal of the term fatigue, as well its focus 
on post-exertional illness which has long been considered a cardinal symptom of the illness 
(Carruthers et al., 2003). To meet SEID criteria, a patient must evidence substantial impairment 
in functioning, unrefreshing sleep, post-exertional malaise, and either cognitive impairment or 
orthostatic intolerance. These criteria are similar to the Clinical Canadian Criteria (Carruthers et 
al., 2003) with regards to requiring core symptoms, but are also similar to the Fukuda et al. 
criteria (1994) as the symptom requirement has once again been set to four. The SEID criteria 
are also the first to specify orthostatic intolerance rather than autonomic dysfunction more 
broadly. Jason, Sunnquist et al. (2015) found that the SEID criteria select a group of patients 
quite comparable to those selected by the Fukuda criteria (1994), and that a greater percentage of 
patients meet SEID than the Clinical Canadian Criteria (Carruthers et al., 2003). However, the 
SEID criteria do not specify any exclusionary illnesses and its use may lead to a significantly 
higher prevalence rate and inappropriate inclusion of individuals with primary MDD (Jason, 
Sunnquist, Kot & Brown, 2015).  
Notably, before the illness was referred to as CFS in the US, an anonymous 1956 
editorial in the British journal the Lancet referred to the illness as “benign myalgic 
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encephalomyelitis.” Ramsay (a British physician who oversaw an outbreak in London hospitals 
in the 1950s) later published his own criteria, specifically using the term ME (1988). His work 
has generated many other ME-based case definitions: the London criteria (Tyrrell et al., 1994), 
the Nightingale definition (Hyde, 2007), and the Goudsmit et al. criteria (2009). In contrast to the 
definitions described above, Ramsay did not consider fatigue to be the hallmark symptom of ME, 
but rather “muscle fatigability after minimal exertion” and he believed strongly in central 
nervous system involvement (1988). Many of the ME theorists influenced by Ramsay believe 
ME to be distinctive from CFS, and consider ME to be a more severe neurological illness, 
characterized by a sudden onset (Goudsmit et al., 2009). Thus, the relationships between ME, 
CFS, ME/CFS and SEID remain ambiguous and controversial, with some researchers treating 
these illnesses as one condition under an umbrella term of ME/CFS (Carruthers et al., 2003; 
Carruthers et al., 2011; IOM, 2015), and others suggesting that these are distinct entities that 
must be studied separately (Goudsmit et al., Hyde).  
While similar themes emerge across the case definitions for CFS, ME, ME/CFS and 
SEID outlined above, they diverge substantially on which symptoms should be required for a 
diagnosis. Clarifying the “core” symptoms for a diagnosis of ME and CFS has become a focus 
for the field, as has the notion that case definitions should be arrived at empirically rather than be 
based upon expert, clinical consensus. It has been suggested that consistent inclusion of 
homogenous patient groups into studies, as well as identification of phenotypical subtypes of 
patients, could assist in the pursuit of biomarkers for ME and CFS (Nacul, Lacerda, Pheby et al., 
2011), which would ultimately allow for a more circumscribed investigation into potential 
treatments.  
Core Symptoms of ME and CFS 
 
 
 
10 
One common approach to establishing “core symptoms” of ME and CFS has been to 
examine which symptoms best distinguish between individuals with ME and CFS and control 
groups (e.g., healthy groups, groups with other illnesses). A number of statistical approaches 
have been utilized in the literature to address the question of what should be considered “core” to 
this illness. Hawk, Jason and Torres-Harding (2006) employed stepwise discriminant function 
analysis to examine which of the eight Fukuda et al. (1994) symptoms could best distinguish 
individuals with ME and CFS from those with major depressive disorder. The authors found that 
when entering severity ratings for the eight Fukuda symptoms into the discriminant function 
analysis, post-exertional malaise, unrefreshing sleep and impaired memory/concentration were 
the best predictors of group membership, correctly classifying 91.1% of cases. Using Receiver 
Operating Characteristic curve analysis (ROC), Jason, Jessen and colleagues (2009) found that 
items loading to a post-exertional malaise factor on the ME/CFS Fatigue Types Questionnaire 
had good sensitivity (90%) and specificity (93%) in distinguishing between patients and controls.  
Factor analysis has also been utilized to inform our understanding of “core” ME and CFS 
domains. Brown and Jason (2014) employed an exploratory factor analysis with a well-defined 
patient sample on a comprehensive list of 54 ME and CFS-related symptoms, and a three-factor 
solution was found to fit the data. Two of these factors were easily interpretable, and provided 
support for both post-exertional malaise and neurocognitive impairment as core domains of the 
illness. A third factor encompassed items relating to symptom domains that have been 
considered secondary such as neuroendocrine, autonomic and immune. These findings of a post-
exertional malaise factor were in line with other factor analytic studies that found post-exertional 
factors in other symptom inventories (Arroll & Senior, 2009; Friedberg, Dechene, McKenzie, & 
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Fontanetta, 2000; Jason, Corradi & Torres-Harding, 2007; Jason et al., 2015; Nisenbaum, Reyes, 
Unger & Reeves, 2004). 
Recently, more advanced statistical methods that utilize computer learning techniques 
have been implemented to determine which symptoms best distinguish patients with ME and 
CFS from other groups using large datasets. Using a technique called data mining, Jason, 
Skendrovic, et al. (2011) found that the inability to concentrate, post-exertional malaise and 
unrefreshing sleep were the best symptom discriminators between patients with ME and CFS and 
controls. A more recent study that employed dating mining with a larger sample and empirically 
established severity thresholds, found that fatigue, post-exertional malaise, neurocognitive 
dysfunction, and unrefreshing sleep differentiated ME and CFS patients from controls with good 
accuracy (Jason, Kot, et al., 2015). When the authors utilized that four-symptom criteria to 
categorize patients, they found that this identified group was significantly more functionally 
impaired than patients who did not meet these criteria. Interestingly, this empirically derived 
case definition has some similarities to the recent, consensus-based SEID criteria that called for 
post-exertional malaise, unrefreshing sleep, and either cognitive dysfunction or orthostatic 
intolerance to be present for a diagnosis (IOM, 2015). Given the results of these previous studies 
and the move toward considering post-exertional malaise a “core” symptom of this illness in the 
most recently proposed SEID case definition, the present review and subsequent meta-analysis 
will focus solely on this symptom. 
Post-Exertional Malaise 
 
Post-exertional malaise (PEM), also referred to as post-exertional neuroimmune 
exhaustion (Carruthers et al., 2011), is included in most case definitions for ME and CFS, 
although the description of this symptom varies across criteria. The Fukuda et al. criteria (1994) 
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simply refer to it as “postexertional malaise lasting more than 24 hours,” whereas the Clinical 
Canadian Criteria (Carruthers et al., 2003) provide much greater specificity, “an inappropriate 
loss of physical and mental stamina, rapid muscular and cognitive fatigability… and a tendency 
for other associated symptoms to worsen.” The newest criteria for the illness, SEID (IOM, 2015) 
describe PEM as “prolonged exacerbation of a patient’s baseline symptoms after 
physical/cognitive/orthostatic stress; [it] may be delayed relative to the trigger.” PEM is 
considered cardinal or required for diagnosis under many case definitions (Carruthers et al., 
2003; Carruthers et al., 2011; Hyde, 2007; Ramsay, David, Wessely, Pelosi & Dowsett, 1988) 
but is not required for diagnosis using the Fukuda et al. (1994) or Empiric criteria (Reeves et al., 
2005). A recent article that examined 53 unique ME and CFS patient samples all meeting the 
Fukuda criteria, found that between 24.7-100% of these patient samples had PEM, with a mean 
of 85% (McManimen et al., 2015).  
However described or defined, PEM is often referred to as the most debilitating aspect of 
the ME and CFS symptom complex by patients (FDA, 2013), leading to profound reductions in 
functioning (Davenport, Stevens, Baroni, Van Ness & Snell, 2011). Further, PEM is often cited 
as a primary reason that treatment protocols based upon vigorous, incremental exercise may be 
inappropriate for individuals with this illness (Nijs, Paul & Wallman, 2008). Those researchers 
and clinicians who endorse a more psychogenic explanation for the illness consider PEM the 
result of deconditioning or a learned fear of activity, and encourage patients to treat their illness 
with exercise or cognitive behavioral therapy to learn strategies for reevaluating certain illness 
cognitions and adopting recovery focused cognitions (Surawy, Hackmann, Hawton & Sharpe, 
1995; White et al., 2011). However, the majority of patients prefer pacing strategies (Shepherd, 
2001), whereby they learn to assess and stay within their “energy envelope” (Jason, Benton, 
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Torres-Harding & Muldowney, 2009) to avoid PEM, rather than pushing themselves beyond 
their envelope as recommended by many exercise-based therapies. Learning to stay within one’s 
energy envelope has been associated with improved physical functioning and less PEM for some 
patients (Brown, Evans, Jones & Jason, 2013). 
Subjective Reporting of Post-Exertional Malaise 
 
Given the varied case definitional descriptions of PEM, assessing and operationalizing 
PEM in both clinical and research settings has been a challenge for the field. A number of self-
report measures have been developed and validated to assess for PEM in patients, including the 
ME/CFS Fatigue Types Questionnaire (Jason, Jessen et al., 2009), the Symptom Inventory 
(Wagner et al., 2005), the CFS Screening Questionnaire (Jason, Ropacki et al., 1997), the 
Medical Questionnaire (Komaroff & Buchwald, 1991), and the DePaul Symptom Questionnaire 
(Jason, Evans, et al., 2010). These questionnaires utilize varying symptom descriptions and 
question stems to elicit a patient’s experience of PEM. For example, the DePaul Symptom 
Questionnaire asks respondents to rate five PEM-related items on frequency and severity Likert-
scales (e.g., “Dead, heavy feeling after starting to exercise”; “Next day soreness or fatigue after 
non-strenuous, everyday activities”; “Mentally tired after the slightest effort,” etc.), whereas the 
Symptom Inventory simply asks respondents about “unusual fatigue after exertion.”  
In a recent study, Jason, Evans, So, Scott and Brown (2015) applied an item that is 
commonly used to define PEM according to the Fukuda criteria (taken from the CFS Screening 
Questionnaire), “Do you feel generally worse than usual or fatigued for 24 hours or more after 
you have exercised?” to a clinically evaluated sample of patients with ME and CFS. 
Approximately 25% of the patients responded “no” to this question. However, when this 
symptom was probed differently (e.g., by a physician or by the item: “Do you experience high 
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levels of fatigue or weakness following normal daily activity?”) all of the patients appeared to 
have PEM. Similarly, Jason, King and colleagues (1999) found that within a clinically evaluated 
ME and CFS sample, the percentage of the sample endorsing PEM ranged from 40-93%, 
dependent upon how the symptom was operationalized. The results from these studies 
demonstrate the critical role symptom operationalization plays in ME and CFS diagnosis. 
Although self-reported PEM has been found to be a sensitive and specific discriminator between 
ME and CFS patients and healthy controls, as well as between ME and CFS patients and 
depressed individuals (Hawk, Jason & Torres-Harding, 2006), the varied approach to PEM 
assessment across studies makes it difficult to interpret the true occurrence of self-reported PEM 
in patients.   
It has been suggested that PEM is a core symptom of ME and CFS, and capable of 
discriminating between patients and controls. It is required for formal diagnosis under many case 
definitions. However, to date there have been no meta-analyses of PEM findings to examine the 
true strength of the PEM phenomenon in ME and CFS samples. Thus, studies that assess PEM in 
ME and CFS samples (as contrasted to controls) are appropriate for meta-analysis. The present 
study will extract and pool odds ratios from studies that report on occurrence of self-reported 
PEM in patients and controls. The resulting mean effect size will provide a better estimate of the 
true differences between patients with ME and CFS and controls on PEM, which could provide 
evidence for or against the claim that PEM distinguishes between patients and controls well and 
should be considered a required, cardinal or core symptom of ME and CFS.  
Study-Level Moderators 
 
 Given the substantial variability observed across studies of ME and CFS on a number of 
methodological design decisions, there are many potential study-level factors that may impact 
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the outcome of a study beyond group membership (ME and CFS or control). That is, certain 
aspects of a study’s design may result in a larger or smaller observed difference between patients 
and controls on PEM outcomes. 
Recruitment method. ME and CFS patient samples are drawn from a number of 
sources, and this may result in substantial variability between studies. Patients may be identified 
for study participation from primary care, from tertiary (or specialized care) settings, through 
random community-based methods, or through convenience methods. Patients identified through 
tertiary care settings have been found to be more severely ill than patients from community-
based samples (Jason, Plioplys, Torres-Harding & Corradi, 2003). Further, patients identified 
using randomized community approaches tend to be less severely ill and are more likely to be 
receiving a diagnosis for the first time compared to patients recruited from primary or tertiary 
care (Jason, Porter et al., 2009). Community-based recruitment also results in more ethnically 
and socioeconomically diverse samples, because these recruitment methods are not biased to 
only select for individuals with access to healthcare (Jason, Taylor, Kennedy, et al., 2000). 
Finally, convenience methods such as online recruitment or recruiting through support groups 
will likely result in patient samples that are similar to tertiary care samples as these are likely 
individuals that identify with this illness and are actively involved in ME and CFS communities 
(Jason, Sunnquist, et al., 2015). Thus, the method of patient recruitment utilized in the studies to 
be included in the present meta-analysis may be an important moderator of the observed 
differences between ME and CFS and controls on subjective PEM experience. It is hypothesized 
that studies that recruit from tertiary care settings or utilize convenience methods may select for 
patients with more severe symptomatology, whereas studies that recruit using randomized, 
community-based methods may have milder symptomatology. Thus, the effect of the PEM 
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phenomenon may be significantly greater in studies that compare controls to patients recruited 
from tertiary care or through convenience sampling than in studies that utilize community-based 
methods.  
Diagnosis. Once a patient is recruited and brought into a study, the method of ME and 
CFS diagnostic confirmation may also vary across studies. Many studies employ thorough 
physical and psychiatric evaluations to diagnosis ME and CFS, while other studies rely upon 
self-reported ME and CFS or documentation from an outside medical provider to confirm 
diagnosis. Clinically evaluated patient samples are more homogenous with regards to 
symptomatology compared to non-clinically evaluated patient samples (Johnston, Brenu, Staines 
& Marshall-Gradisnik, 2013). Further, accepting self-reported diagnoses with no documentation 
may introduce significant bias into a study, and it has been suggested that prevalence studies 
based upon self-reported ME or CFS should be interpreted cautiously (Johnston et al., 2013). It is 
hypothesized that studies that employ thorough evaluations may result in more profound 
differences on PEM outcomes between patients and controls, as these studies may avoid 
erroneous inclusion of non-patients or patients with other conditions (as might occur with self-
reported ME and CFS). Documentation from outside physicians may also not be sufficient as 
they may not have the clinical expertise that specialists have, as has been demonstrated by many 
studies of physicians (Anderson, Jason, Hlavaty, Porter & Cudia, 2011; Bayliss et al., 2014).  
Case definition. The case definition adhered to for diagnosis would also be a desirable 
moderator to examine, given the breadth of findings from case definitional comparison studies, 
but the vast majority of studies employ the Fukuda et al. criteria (1994) and this may make 
subgroup analyses difficult. 
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Symptom measurement. Many different approaches to assessing symptomatology are 
represented in the literature. Some studies utilize a validated and accepted self-report tool to 
assess symptomatology such as the CDC Symptom Inventory (Wagner et al., 2005), the DePaul 
Symptom Questionnaire (Jason, Evans et al., 2010) or the CFS Questionnaire (Komaroff et al., 
1996), while other studies utilize non-validated tools to assess symptoms (e.g., a set of questions 
developed for a study that are not used by other researchers). Studies may also rely upon 
interviewing alone. Definitions of “presence” or “occurrence” of a symptom also vary across 
studies (Jason, King, Taylor & Kennedy, 2000). While the major case definitions (Fukuda et al., 
1994; Carruthers et al., 2003) state that the symptom complex must be present for at least six 
months, it is unclear if a symptom has to occur at a certain severity and frequency to be 
considered present. Jason, Evans et al. (2010) attempted to operationalize the Clinical Canadian 
Criteria (Carruthers et al., 2003) by recommending that symptoms must be rated as occurring at 
least “half the time” and being of at least “moderate” severity to count as truly “occurring.” 
However, many investigators do not offer this level of specificity and simply rely upon 
endorsement of a symptom at any intensity to count as present. For studies that provide 
additional information about symptom assessment, additional moderators of effect size can be 
investigated. For example, how PEM was assessed (e.g., through a validated tool, physician 
assessment or a non-validated tool) will be treated as a moderator, as well as how “occurrence” 
of PEM was defined (e.g., utilizing intensity thresholds versus occurrence). It is hypothesized 
that studies that utilize a validated questionnaire to assess PEM and apply some sort of intensity 
thresholding may find a greater effect than studies that do not. 
Control selection. Many types of controls are represented in the literature as comparison 
samples, including physically and mentally “healthy” samples, or sedentary but otherwise 
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healthy samples. Another common approach is to utilize other illness groups as controls, such as 
samples with depressive disorders or other samples that may experience some shared symptoms 
such as severe fatigue (e.g. lupus, multiple sclerosis, cancer). It is hypothesized that studies that 
utilize healthy controls will find a greater effect than studies that utilize other illness groups.  
Considerable effort has focused on establishing a reliable and valid case definition for 
ME and CFS and on investigating potential diagnostic tests for the illness. However, these efforts 
have been complicated by an over-reliance on clinical consensus for establishing case 
definitions, and inconsistent application of case definitions by researchers across study sites. This 
has resulted in the absence of an empirically-based case definition for ME and CFS, as well as 
failed replication studies on potential diagnostic tests and biomarkers. One step of empirically-
driven case definition development is establishing which symptoms might be able to discriminate 
well between patients with ME and CFS and controls (healthy controls or other illness groups). 
As reviewed above, one symptom thought to be “core” or “cardinal” to this illness is post-
exertional malaise (PEM). However, to date, there have been no meta-analyses of the findings 
from studies that investigate PEM differences between patients and controls. Thus, a meta-
analytic approach to synthesizing the data on PEM and an investigation of potential moderators 
of effect size in the literature are both logical next steps in case definition development. It is 
hypothesized that the presence of PEM is associated with an increased odds of having ME and 
CFS as measured by a 95% confidence interval around the mean odds ratio that does not contain 
the null value, log odds ratio = 0. 
Method 
Overview of Meta-Analysis 
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 Meta-analysis is a quantitative technique for summarizing results of studies that attempt 
to measure the same phenomenon (Card, 2011). The primary unit of interest in meta-analysis is 
the effect size, or the strength or practical importance of a study’s finding beyond its statistical 
significance. Meta-analysis also allows for measurement of effect-size heterogeneity in the 
literature, and if significant heterogeneity is detected, allows for an investigation of what 
observable, study-level characteristics might be driving this heterogeneity. Meta-analysis is a 
systematic and transparent process which is becoming increasingly common in the social, 
physical and medical sciences. It consists of the following steps: establishing study inclusion and 
exclusion criteria; conducting a thorough and systematic review of the literature for appropriate 
studies; coding the subsequent sample of studies on key characteristics utilizing a standardized 
coding protocol; computing effect sizes for individual studies; calculating the overall mean effect 
size and confidence interval for the phenomenon of interest; investigating the presence of and 
contributors to heterogeneity of effect size in the sample of studies utilizing subgroup analysis; 
and finally, considering and addressing the potential impact of publication bias on the findings. 
The guidance and recommendations of Card (2011) primarily shaped this writer’s understanding 
of the stages of a rigorous meta-analysis.   
Inclusion Criteria 
 
 Studies were included that met the following criteria: (a) they reported on the presence or 
occurrence of PEM in both patients with ME and CFS and controls, (b) they reported sufficient 
information for computing effect size, (c) they were published between January 1988 and 
December 2016, (d) they investigated an adult sample (18 years or older), (e) they presented data 
from independent samples, and (f) they were available in English. 
Literature Search 
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 Eligible studies were identified through searches of two major databases, PsycINFO and 
PubMed. The most recently published meta-analysis in the ME and CFS field (Cockshell & 
Mathias, 2010) relied upon the following search terms: “chronic fatigue syndrome”; “chronic 
fatigue and immune dysfunction syndrome”; “chronic fatigue disorder”; “chronic fatigue-
fibromyalgia syndrome”; “chronic infectious mononucleosis-like syndrome”; “myalgic 
encephalomyelitis”; “myalgic encephalopathy”; “post viral fatigue syndrome”; and “royal free 
disease.” These terms and an additional term, “myalgic encephalomyelitis/chronic fatigue 
syndrome” were included. To avoid potential publication bias, the ProQuest Dissertation and 
Theses Database was also searched. 
Coding Procedure 
 
The author identified articles for inclusion and further coding by reviewing the title and 
abstract. If necessary, the full article was scanned to determine eligibility. Relevant study 
information was recorded using a standardized coding protocol developed by the author (see 
Appendix A). This coding protocol was developed with the proposed effect size and moderator 
analyses in mind, as well as other potentially relevant information.  
Analytic Strategy 
 
 Computing effect size. Effect sizes were computed as odds ratios (OR) from outcomes 
from the two independent groups (patients and controls). An OR describes the strength of 
association between two binary variables (Bland, 2000). For the current study, the two binary 
variables were “presence of ME and CFS” (yes/no) and “presence of PEM” (yes/no). In order to 
account for the sample size of a study the OR was transformed to the log scale, and then 
weighted by the inverse variance as proposed by Lipsey and Wilson (2001) before being 
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averaged. This sample size weighting is done because larger studies are thought to more 
precisely estimate the population effect size than smaller studies.  
 Statistical model. A random effects model was used due to the assumed significant 
variability between the studies. This is a more conservative approach than utilizing a fixed 
effects model, as a random effects model accounts for random error as well as study-level 
variability (e.g., research design, sample characteristics, etc.) (Hunter & Schmidt, 2000). Given 
what is known about the heterogeneity of study design within the ME and CFS literature as 
discussed in the introduction, this approach is most appropriate. Further, this random effects 
approach allows for a more valid generalization of the present findings to studies that aren’t 
included in the analysis (Hedges & Vevea, 1998). The statistical packages “metafor” version 1.9-
9 (Viechtbauer, 2016) and “meta” version 4.8-1 (Schwarzer, 2017) for R were used for all 
analyses.  
 Heterogeneity analyses. Variability in effect size across studies was statistically tested 
by investigating the Cochran Q statistic (Cochran, 1954). The null hypothesis for the Q statistic 
states that variance in effect size is due to random error alone, and is not due to true differences 
between studies. If the Q is statistically significant, this suggests that the variance of effect size is 
significantly greater than 0, and thus the null hypothesis is rejected because at least some of this 
variability might be explained by known study-level characteristics. Moderator analyses may 
then be considered appropriate in order to investigate the potential factors contributing to the 
effect size variability. However, it has been suggested that the Q statistic may not do well at 
detecting true heterogeneity due to power issues and that a failure to reject the null should not be 
taken as evidence of effect size homogeneity (Higgins, Thompson, Deeks & Altman, 2003). An 
alternative statistic, I2, developed by Higgins and Thompson (2002), measures the inconsistency 
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of results across studies. This statistic provides the percentage of variation across studies 
included in the meta-analysis that is due to true heterogeneity rather than random error (ranging 
from 0-100%). Both the Q and I2 statistics were investigated and considered before moving 
forward with moderator analyses. 
 Moderator analyses. Investigating moderators using sub-group analysis in a meta-
analysis can be thought of as analogous to ANOVA in an individual study; groups defined by 
their level of some independent variable X (e.g., patient or control) are compared on the outcome 
Y (e.g. fatigue level). In sub-group analysis within a meta-analysis, groups are defined by their 
level of some observable study characteristic (e.g. patient recruitment method, type of control 
sample, etc.), and compared on the outcome of mean effect size. Initially, a meta-regression with 
a mixed-effects model and maximum likelihood estimation was utilized to see which potential 
moderators significantly contributed to effect size variability (van Houwelingen, Arends & 
Stijnen, 2002). Those moderators found to be significant were further investigated by comparing 
the resulting sub-groups for significant differences within a fixed-effects model by computing 
the Q-between statistic based on analysis of variance (Borenstein, Hedges, Higgins & Rothstein, 
2009). A Bonferroni correction was utilized based on the number of planned comparisons; 
subgroup contrasts had to be significant at p<.001. The within-group Cochran’s Q statistic was 
also computed for each subgroup of studies just as it was computed for the total set of studies.  
 Investigation of publication bias. Publication bias is said to occur when peer-reviewed, 
published articles in the literature (typically the basis for systematic reviews and meta-analyses) 
are not truly representative of the group of studies that have actually been conducted on a given 
phenomenon (Rothstein, Sutton & Borenstein, 2005). The “file-drawer effect” refers to the 
tendency for studies with significant and positive results to be published more often than studies 
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that fail to reject the null hypothesis or studies that result in findings in the opposite direction of 
what was hypothesized, and thus these non-significant or negative findings are “placed in the 
file-drawer” rather than being submitted for publication or disseminated (Rosenthal, 1979). Thus, 
systematic reviews and meta-analyses may be biased due to the fact that studies that are readily 
available for analysis likely show a stronger overall effect of a given phenomenon than if all 
conducted studies were included. One strategy to combat publication bias before beginning the 
analysis, as mentioned above, is the inclusion of unpublished (but accessible) dissertations and 
theses. Once the sample of studies to be included was established, and the meta-analysis was 
conducted, a number of statistical approaches were used to investigate the potential impact of 
publication bias on the results. The following approaches, as described by Card (2011), were 
used. 
 Funnel plot. A funnel plot allows for a graphical representation of potential publication 
bias, and is a simple scatterplot. The effect sizes of all studies were plotted (on the x-axis) 
relative to a measure of study size (on the y-axis; standard error was utilized for the present 
study), and the resulting scatterplot was evaluated for symmetry and a triangular shape.  
Rank correlation test. As developed by Begg and Mazumdar (1994), a more objective 
assessment of funnel plot symmetry involves the computation of an adjusted rank correlation 
between effect size and standard error for all included studies. For each study, the variance of the 
effect size from the mean effect size and the standardized effect size are both computed and used 
to estimate Kendall’s rank correlation. If power is adequate, and the correlation is significant, 
this is indicative of funnel plot asymmetry and potential publication bias.  
Egger’s linear regression. Another evaluation of funnel plot symmetry, as developed by 
Sterne and Egger (2005), involves regressing the standardized effect sizes onto the standard 
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errors. In the resulting regression equation: 𝑧𝑧𝑖𝑖 =  𝐵𝐵0 + 𝐵𝐵1 +  𝑒𝑒1 ; the slope (𝐵𝐵1) is the mean 
effect size and the intercept (𝐵𝐵0) is the measure of bias. Thus, a nonzero intercept value is 
indicative of funnel plot asymmetry or potential publication bias.  
Failsafe N. Failsafe N refers to the number of excluded studies with an average effect 
size of zero that would have to be included in the meta-analysis to lower the observed mean 
effect size to a non-significant level. Rosenthal (1979) introduced this concept, and it can be 
thought of as the number of studies that found (on average) no effect that would have to have 
been “filed away” in order to make the present meta-analysis meaningless. The larger the 
number, the more robust to publication bias the findings can be thought to be.  
Results 
Search Outcome 
 
 The search of PubMed resulted in 6,208 publications, 26 of which met inclusion criteria. 
The search of PsycInfo resulted in 788 additional, unique publications, only three of which met 
inclusion criteria. The search of ProQuest Dissertations & Theses Global resulted in 157 
manuscripts. Of these, only two met inclusion criteria. In the case of duplicate samples, only the 
first study found that utilized the sample was included. Table 1 includes a description of all 
included studies (N=31) on key study characteristics. The complete list of APA citations is 
included as Appendix B.  
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Table 1. Summary of Studies (N = 31) 
 
Study Patient Recruitment Diagnosis Case Def. PEM Assessment Controls 
Arpino et al., 1993 Primary Care MD- Study Fukuda & 
Holmes 
Interview; Occur. CF 
Bennett et al., 2014 Unknown MD- Study Fukuda Interview; Occur. MDD 
Buchwald & Garrity, 1994 Tertiary Care MD- Study Holmes NV Quest.; Occur. FM & MCS 
Buchwald et al., 1995 Primary Care MD- Study Fukuda NV Quest.; Occur. CF & HC 
Cockshell & Mathias, 2013 Primary & 
Tertiary Care 
MD- Study Fukuda CDC-SI; Occur. HC 
De Becker et al., 2001 Tertiary Care MD- Study Fukuda  GSC; Sev. CF 
Davenport et al., 2011 Convenience  Self-report Fukuda NV Quest.; Occur. HC 
Eymard et al., 1993 Tertiary Care MD- Study Holmes Interview; Occur. CF 
Gaudino et al., 1997 Tertiary Care MD- Study Fukuda NV Quest.; Freq. Lyme 
Gibson et al., 1993 Tertiary Care MD- Outside Oxford Interview; Occur. HC 
Hawk et al., 2006 Convenience MD- Outside Fukuda NV Quest.; Occur. MDD & HC 
Jason et al., 2003 Random- CB MD- Study Fukuda & 
London 
NV Quest.; Occur. CF 
Jason et al., 2014 Convenience MD- Outside Fukuda DSQ; Freq. & Sev. HC 
Jason et al., 2015a Convenience MD- Study Fukuda Interview; Occur. MS, Lupus & 
HC 
Jason et al., 2015b Convenience  MD- Outside Fukuda NV Quest.; Occur. MDD & HC 
Jason et al., 2015c Random- CB MD- Study Fukuda Interview; Occur. CF & HC 
Jason et al., 2015d Convenience MD- Outside Fukuda CDC SI; Freq./Sev. MDD 
Kaemingk, 1992* Tertiary Care MD- Outside Unknown NV Quest.; Sev. HC 
Keijmel et al., 2015 Tertiary Care MD-Outside Fukuda NV Quest.; Occur. Q-Fever 
Lane et al., 1991 Tertiary Care MD- Study Holmes Interview; Occur. CF 
McDonald et al., 2014 Tertiary Care Self-report Unknown NV Quest.; Occur. POTS 
MacDonald et al., 1996 Tertiary Care MD- Study Holmes Interview; Freq. HC 
Nisenbaum et al., 2004 Random- CB MD- Study Fukuda NV Quest.; Occur. CF & HC 
Okamoto et al., 2012 Tertiary Care MD- Study Fukuda  Unknown POTS 
Patrick et al., 2015 Convenience MD- Study Canadian NV Quest.; Occur. Lyme, Lupus 
& HC 
Strickland et al., 2001 Tertiary Care MD- Outside Fukuda NV Quest.; Occur. CF 
Suhadolnik et al., 2004 Tertiary Care MD- Study Fukuda & 
Holmes 
NV Quest.; Occur. HC & MDD 
VanNess et al., 2010 Tertiary Care MD- Outside Fukuda NV Quest.; Occur. HC 
Vercoulen et al., 1996 Tertiary Care MD- Study Unknown NV Quest., Freq. HC & MS 
Wagner, 1997* Other MD- Review Fukuda  NV Quest., Occur. CF  
Wessely et al., 1996 Primary Care MD- Study  Fukuda NV Quest., Occur. HC 
 
*Dissertation; Random-CB= Randomized community-based sampling; Occur.= Reported occurrence of PEM only 
w/o thresholding; NV Quest.= Non-validated questionnaire used to assess PEM; CDC-SI= Centers for Disease 
Control Symptom Inventory used to assess PEM; GSC= Goldstein Symptom Checklist used to assess PEM; Sev.= 
Utilized some threshold of severity to assess PEM; Freq.= Utilized some threshold of frequency to assess PEM; 
DSQ= DePaul Symptom Questionnaire used to assess PEM; CF= chronic fatigue or idiopathic chronic fatigue; 
MDD= major depressive disorder; FM= fibromyalgia; MCS= multiple chemical sensitivities; HC= healthy controls; 
MS= multiple sclerosis; POTS= postural orthostatic tachycardia syndrome  
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Effect Size 
 
 The weighted mean effect size (log odds ratio) with a 95% confidence interval for all 
studies was found to be 2.34 [1.81-2.87]. Thus, the odds of the presence of PEM being 
associated with an ME and CFS diagnosis is roughly 10.4 times more likely than the presence of 
PEM being associated with a non-ME and CFS diagnosis. The Forest Plot is a visual 
representation of the effect size and 95% confidence interval of all studies included in the meta-
analysis, with studies listed on the vertical axis, and effect sizes on the horizontal axis of the 
figure (Card, 2011). The weighted mean effect size of all studies is indicated with a black 
diamond, as well as a dotted line indicating the null result (e.g., a log odds ratio value of 0). The 
Forest Plot is included as Figure 1.  
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Figure 1. Forest Plot, Random Effects Model 
 
Legend: P-PEM, individuals w/ ME and CFS w/ post-exertional malaise; P-No PEM, individuals 
w/ ME and CFS w/o post-exertional malaise; C-PEM, controls w/ post-exertional malaise; C-No 
PEM, controls w/o post-exertional malaise; log(OR), log odds ratio 
 
Tests of Study Heterogeneity 
 
 The Cochran Q statistic (Cochran, 1954) was significant, X2 (30) =145.48, p<.001. The I2 
(Higgins & Thompson, 2002) was 85.8%, suggesting that a considerable percentage of the 
variability in effect estimates is due to true heterogeneity. Together both results suggest that the 
included studies had significant effect size heterogeneity that is likely not accounted for by 
random error alone and thus moderator analyses were appropriate to investigate. 
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Moderator Findings 
 
 A summary of subgroup mean effect size comparisons are included as Table 2. All 
subgroups of studies including more than one study had a significant within group Q statistic 
aside from one subgroup (dissertation). This suggests that significant effect size variability exists 
even within subgroups of studies that share certain moderators. The moderators with non-
significant findings within the meta-regression included: publication status, method of diagnosis, 
case definition, mode of PEM assessment, and thresholding. That is, these were not found to be 
significant moderators of overall effect size variability and thus were not further investigated. 
 Patient recruitment strategy and control type were found to be significant moderators 
within the meta-regression. Regarding patient recruitment strategy, in studies that utilized a 
convenience method for recruiting individuals with ME and CFS the effect was found to be 
significantly greater than in studies that recruited individuals with ME and CFS through tertiary 
care and primary care settings. Regarding control type, in studies that utilized healthy controls or 
a combination of healthy controls and individuals with major depressive disorder, the effect was 
found to be significantly greater than in studies that utilized chronically fatigued individuals, 
individuals with POTS, or the “other” category which was composed of studies that utilized 
combinations of other illness groups such as multiple sclerosis, lupus or Lyme disease.  
Table 2. Sub-Group Comparisons  
Moderators log(odds ratio) # of studies Qwithin group 
Publication Status    
Published 2.33 29 137.32** 
Dissertation 2.65 2 6.82 
Recruitment Approach1    
Tertiary Care 1.85a 15 55.8** 
Convenience 3.93ab 7 6.59** 
Primary Care 1.57b 3 2.22** 
Randomized Community-Based 2 3 15.94** 
Other 2 3 19.54* 
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Diagnosis    
MD- Study 2.22 18 77.89** 
MD- Outside 2.89 10 52.76** 
Self-Report 0.95 2 3.03* 
Other 1.04 1 0 
Case Definition    
Fukuda 2.48 19 90.01** 
Holmes 1.76 4 7.47** 
Unknown 1.23 3 8.21** 
Other 2.68 3 8.29** 
Fukuda & Holmes 2.59 2 16.79* 
PEM Mode of Assessment    
Non-Validated Questionnaire 2.14 18 85.56** 
Interview 1.96 8 13.01** 
Validated Questionnaire 3.61 4 43.49** 
Other 1.74 1 0 
PEM Thresholding    
No 2.33 23 99.97** 
Yes 2.48 7 45.03** 
Other 1.74 1 0 
Control1    
Healthy Controls (HC) 3.7abc 8 32.23** 
Chronic Fatigue (CF) 1.5ad 7 6.97** 
Other 1.13be 6 13.47** 
CF & HC 2.51 3 7.52** 
MDD & HC 4.43def 3 .31** 
MDD (major depressive disorder) 2.46 2 .48** 
POTS 1.04cf 2 1.58** 
 
POTS = postural orthostatic tachycardia syndrome 
1Significant moderator category based upon meta-regression  
*p<.05, **p<.001 on Qwithin group 
Subscripts within a column for a given moderator reveal a significant contrast on Qbetween group at p<.001 
 
Publication Bias Findings 
 
 The Funnel Plot is included as Figure 2. Although this is a subjective visual assessment, 
studies with small sample sizes appear to be more variable on effect size (representing the “base” 
of the triangle), and as sample sizes increase the variability in effect size decreases (representing 
the “point” of the triangle). The shape suggests that publication bias may not be an issue. 
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Additionally, the Fail-Safe N was found to be 4,811 (p < .001) utilizing the Rosenthal Approach. 
Thus, 4,811 studies with an average effect size of zero would have to be included in the meta-
analysis to lower the observed mean effect size to a non-significant level, suggesting that the 
present results are quite robust to potential publication bias. Begg-Mazumdar’s rank correlation 
test, an objective assessment of funnel plot asymmetry (Kendall’s tau = 0.19, p=.14) suggests 
publication bias is not an issue but power may be too low to detect significance.  Egger’s linear 
regression approach found the intercept value (estimate of potential bias) to = 1.07, p = .02 
which suggests possible publication bias. However, Higgins and Green (2011) suggest that when 
utilizing odds-ratios, both Begg-Mazumdar’s and Egger’s approaches may be problematic due to 
the natural correlation of odds-ratios to their standard errors. Taking this into account, and the 
high Fail-Safe N value, the present results seem to be robust to publication bias.  
 
Figure 2. Funnel Plot 
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Discussion 
 The major finding of the present meta-analysis is that the presence of subjectively 
reported post-exertional malaise is 10.4 times more likely to be associated with an ME and CFS 
diagnosis than with control status. This finding can reasonably be considered robust to 
publication bias, and strongly suggests that self-reported PEM discriminates well between ME 
and CFS and controls and has meta-analytic support as a cardinal symptom of the disease. The 
hypothesis that PEM and ME and CFS would be significantly associated is supported. Thus, case 
definitions that require PEM for a diagnosis may be most appropriate for use (e.g., Carruthers et 
al., 2003) and should be relied upon rather than the most commonly utilized polythetic Fukuda et 
al. (1994) criteria.  
Implications of Moderator Analyses  
 
 The total sample of studies (N=31) and all of the study subgroups defined by study-level 
characteristics evidenced significant within-group variability on effect size. Thus, the hypothesis 
that studies on ME and CFS and PEM are heterogeneous on effect size was supported. The 
overall estimate of effect size was significantly impacted by two study-level moderators: patient 
recruitment strategy and control selection. The hypothesis that studies that utilized a healthy 
control group would find a stronger effect was supported by the results. It should be noted that 
neither of the moderators changed the overall pattern of the effect (PEM is strongly associated 
with ME and CFS regardless), but significantly changed the strength of the effect. That is, 
studies that utilized healthy individuals or a combination of healthy individuals and individuals 
with major depressive disorder (MDD) as comparison groups found significantly higher odds of 
ME and CFS being associated with PEM (40.4 times more likely when utilizing healthy 
individuals and 81.5 times more likely when utilizing the combination) than the studies that 
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utilized other disease groups or chronically fatigued groups as comparisons. Surprisingly, the 
group of studies that utilized an MDD-only control group were not significantly different from 
the other disease study subgroups, but this is likely due to low power as just two studies were 
included in the MDD-only group. These findings suggest that PEM may discriminate ME and 
CFS from healthy or depressed individuals more strongly than it discriminates ME and CFS from 
other illness groups. This fits with previous literature suggesting that ME and CFS and MDD are 
distinct entities (Barnden, Crouch, Kwiatek, Burnet & Del Fante, 2015; Christley, Duffy, Everall 
& Martin, 2013). 
When considering the impact of patient recruitment strategy, the effect was much 
stronger in the studies that utilized convenience methods (50.9 times more likely that PEM and 
ME and CFS are associated) than studies recruiting patients from primary or tertiary care 
settings. Thus, the hypothesis that studies that recruit from tertiary care settings or utilize 
convenience methods may select for patients with more severe symptomatology was only 
partially supported. The hypothesis that studies that recruit using randomized, community-based 
methods would have milder symptomatology was not supported. It is somewhat counterintuitive 
that the convenience sampling and tertiary care sampling subgroups were significantly different 
given that these strategies tend to capture similar patient groups (Jason, Sunnquist, et al., 2015). 
The strength of the phenomenon in the convenience sampling subgroup compared to the other 
subgroups may suggest that individuals with ME and CFS that are recruited from support groups 
or online are some of the most profoundly ill.  
 Many of the moderators that were hypothesized to be of import were not significant 
contributors to effect size variability (diagnostic approach, method of PEM assessment, and case 
definition) and thus subgroup comparison hypotheses could not be investigated. Further, the 
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intersections of many of the proposed moderators may have provided more rich information 
(e.g., subgroups defined by their patient recruitment strategy and case definition used) but the 
resulting subgroups would have been too small for comparison. Future meta-analytic studies of 
ME and CFS should investigate subgroups defined by a number of study-level characteristics if 
power allows.   
Limitations  
 
 This study has a number of limitations. Most importantly, the number of studies that met 
inclusion criteria is relatively low (while still being appropriate for meta-analysis). The primary 
reasons studies were excluded was lack of reporting on PEM. Many studies focused exclusively 
on the symptom of fatigue, missing the unique element of post-exertional sickness and symptom 
exacerbation that PEM describes. Other studies reported just one composite somatic symptom 
severity score that didn’t allow for the teasing out of unique symptom occurrence. Ideally, it 
might have been possible to reach out to lead authors about the latter issue to collect this data, 
but this was outside the scope of the present investigation.  
 Regarding publication bias, while an attempt was made to include dissertations and 
theses, many of the abstracts that seemed promising were inaccessible and thus could not be 
included in the present study. After assessing for publication bias, a decision was made not to 
contact leaders in the field for unpublished data from the timeframe of interest due to the large 
result of the Fail-Safe N analysis. However, this could also be considered a limitation.  
 The use of just one coder for the meta-analysis was both a limitation and a strength. This 
may mean that more bias was introduced than if multiple coders were used (Buscemi, Hartling, 
Vandermeer, Tjosvold & Klassen, 2006), but also allowed for more consistency in applying the 
inclusion criteria and in the subsequent coding process. That is, the introduction of bias may 
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have been more systematic than if multiple coders had been utilized. Additionally, while those 
studies that were included provided data on independent samples, it is not possible to be fully 
confident that individuals with ME and CFS were not represented in more than one study.  
Future Directions 
 This meta-analysis was only focused on subjective presence of PEM. While method of 
PEM assessment (thresholding for frequency and severity versus occurrence alone) was 
considered as a moderator, it would also be important to meta-analyze PEM severity outcomes in 
patients versus controls. However, this may be difficult until more researchers begin reporting on 
the intensity of specific symptom domains rather than just reporting composite somatic symptom 
scores. Future meta-analyses of PEM should also focus on studies that investigate objective 
performance on exercise testing, and how well this testing may distinguish between patients and 
controls. Cognitive functioning has already been investigated meta-analytically (Cockshell & 
Mathias, 2010), but other core symptoms of ME and CFS (sleep dysfunction, autonomic 
dysfunction, pain, etc.) could be investigated in a similar way. 
Conclusion 
 
 As the field continues to move toward an empirical approach to ME and CFS case 
definition, it is key to utilize the tool of meta-analysis to quantitatively synthesize results. While 
treatment trials have traditionally been the basis for meta-analyses in the ME and CFS field, 
more attention should be paid to the role of meta-analysis in empirical case definition 
development. Meta-analysis allows for a unique type of systematic communication between 
researchers and permits broader claims to be made about an understanding of phenomena. This 
study highlights the importance of considering not only the mean effect size of a sample of 
studies that purport to study the same outcome, but also how that effect is moderated by the 
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study design choices of researchers. Through increased collaboration, multi-site studies, and 
more consistent adherence to best practices [such as considering the minimum data elements for 
ME and CFS research reports recommended by Jason et al. (2012)], the field can move closer to 
more comparable and replicable investigations. The present study lends strong support for PEM 
as a core symptom of ME and CFS that is capable of distinguishing between individuals with and 
without this disease and should be required under a research case definition. 
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